Oslo, Norway, 19 October 2018 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announced that the company will present results
from the Phase I dose escalation study in perihilar cholangiocarcinoma
(extrahepatic bile duct cancer) at the ESMO 2018 Congress in Munich, Germany (19
- 23 October 2018).
One of the key investigators in the trial, Prof. Jörg Trojan, will present the
poster during the poster display session Sunday 21 October, 12.45 - 13:45 CET in
Hall A3 (presentation number 760P).
The poster will be available at PCI Biotech's website in the section Investors /
Reports and presentation / Other presentations.
The ESMO Congress is the leading European meeting for medical oncology and
nearly 20,000 oncology stakeholders are expected to attend. ESMO 2018 is held at
Messe Munich, Germany 19 - 23 October 2018.
Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms: fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).
Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead fimaChem programme consists of a clinical Phase I/II study in
bile duct cancer, an orphan indication with a high unmet need and without
approved products. fimaVacc applies a unique mode of action to enhance the
essential cytotoxic effect of therapeutic cancer vaccines, which works in
synergy with several other state-of-the-art vaccination technologies. fimaNAc
utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.